Quest Diagnostics to Showcase Cutting-Edge Data on ctDNA MRD Testing at ASCO 2026 Quest Diagnostics will unveil significant new data regarding circulating tumor DNA MRD testing at the 2026 ASCO Gastrointestinal Cancers Symposium in San Francisco.

Quest Diagnostics to Showcase Cutting-Edge Data on ctDNA MRD Testing at ASCO 2026 #United_States #San_Francisco #Quest_Diagnostics #Haystack_MRD #ASCO_Symposium

MVZ HPH Launches Cutting-Edge ctDNA Blood Test for Cancer Monitoring in Germany The MVZ HPH Institute introduces a revolutionary blood test for cancer monitoring in Germany, utilizing Haystack MRD technology to improve patient care.

MVZ HPH Launches Cutting-Edge ctDNA Blood Test for Cancer Monitoring in Germany #Germany #Hamburg #Haystack_MRD #MVZ_HPH #ctDNA_Blood_Test

MVZ HPH Launches ctDNA Blood Test for Enhanced Cancer Monitoring in Europe MVZ HPH Institute introduces a groundbreaking ctDNA blood test for cancer monitoring in Europe using Haystack MRD technology, enhancing treatment insights.

MVZ HPH Launches ctDNA Blood Test for Enhanced Cancer Monitoring in Europe #Germany #Hamburg #ctDNA #Haystack_MRD #MVZ_HPH